VACCINATIONS: All vaccinations delivered by suitably trained pharmacists have always been covered by indemnity insurance as part of the standard PDA membership apart from Covid-19. For new membership renewals after January 1st, 2026, Covid-19 vaccinations are now also automatically covered.

Home  »   Latest News   »   Have your say: Consultation on pharmacy premises fees in Northern Ireland

Have your say: Consultation on pharmacy premises fees in Northern Ireland

The Pharmaceutical Society of Northern Ireland (PSNI) has launched a consultation on pharmacy premises fees, and the PDA is encouraging all members based in Northern Ireland to take the opportunity to share their views.

Sat 20th June 2026 The PDA

Consultations like this are an important part of how professional regulation develops. They provide pharmacists and other stakeholders with a direct opportunity to influence policy decisions that can have long-term implications for the profession, the sector, and ultimately patient care. Pharmacists’ voices matter, and this consultation is a chance to make them heard.

What is being consulted on?

The PSNI is reviewing the level and structure of pharmacy premises fees in Northern Ireland.  The details of the proposed changes are set out in the consultation document, and there are a number of possible options. In Northern Ireland, the annual pharmacy premises retention fee has remained unchanged at £155 since 2011. In comparison, the GPhC annual registration fee was £217 in 2011 and will increase to £441 in September 2026.

This is a significant topic, as premises fees contribute to the overall cost of regulation and help support the work ensuring standards are maintained across the sector.

Why this matters

At present, there is a notable difference between premises fees in Northern Ireland and those in Great Britain (GB). While premises fees in Northern Ireland are substantially lower than GB, it is a different story for the individual pharmacist.

Individual registrants in Northern Ireland pay higher fees compared to their counterparts elsewhere. Pharmacists in Northern Ireland pay £477 to the PSNI to maintain their registration, while in Great Britain, the equivalent fee to the GPhC will increase to £310 from September 2026.

It is also important to note that the number of pharmacists registered with the PSNI has increased from around two thousand in 2011 to around three thousand in 2026, whilst the number of pharmacy premises has remained fairly static. This means that as a proportion of the total annual registrant fee income for the PSNI, the fee contribution paid by pharmacists has grown disproportionately.

These differences raise legitimate questions about how the costs of regulation are distributed across all registrants. Some may feel that the current balance places a greater burden on individual professionals, while others may consider the existing structure appropriate in the local context.

Why pharmacists input is important

Pharmacists and their experience and perspective are essential in shaping a fair and sustainable regulatory framework. Whether working in community pharmacy, hospital settings, or other roles, they are directly affected by how regulatory costs are set and allocated.

This consultation provides an opportunity to reflect on questions such as:

  • Is the current balance between registrant fees and premises fees appropriate?
  • Should there be greater alignment with other parts of the UK or Republic of Ireland?
  • What impact could changes to premises fees have on pharmacy services, employers, and the wider sector?
  • How should the costs of regulation be shared fairly between individuals and organisations?

There is no single ‘right’ answer to these questions, but it is important that the PSNI hears from a wide range of voices before making any changes.

 Take part in the consultation

The PDA recognises that discussions about fees and funding can be sensitive. It is important that all contributions to the consultation are thoughtful, evidence-based, and focused on achieving a fair outcome for the profession as a whole. Members may hold differing views on whether current arrangements represent the right balance or whether changes are needed.

The PDA strongly encourages all members in Northern Ireland to read the consultation document and submit a response before the deadline of 5 pm on Monday 3 August. Even a short response can make a meaningful contribution. By participating, members help ensure that decisions are informed by the realities of practice and reflect the views of those working on the ground.

The PDA is also interested in hearing pharmacists views. Members are encouraged to share their thoughts or a copy of their response to the consultation with [email protected]

This is an opportunity for pharmacists to influence an important decision for the profession in Northern Ireland. The PDA encourages all pharmacists to take part and make their voice count.

Learn more

Not yet a PDA member?

If you have not yet joined the PDA, we encourage you to join today and ask your colleagues to do the same.

Membership is FREE to pharmacy students, trainee pharmacists, and for the first three months of being newly qualified.

JOIN THE PDA TODAY

Read about our key member benefits here.

 

 

 

 

 

 

 

 

The Pharmacists' Defence Association is a company limited by guarantee. Registered in England; Company No 4746656.

The Pharmacists' Defence Association is an appointed representative in respect of insurance mediation activities only of
The Pharmacy Insurance Agency Limited which is registered in England and Wales under company number 2591975
and is authorised and regulated by the Financial Conduct Authority (Register No 307063)

The PDA Union is recognised by the Certification Officer as an independent trade union.

Cookie Use

This website uses cookies to help us provide the best user experience. If you continue browsing you are giving your consent to our use of cookies.

General Guidance Resources Surveys PDA Campaigns Regulations Locums Indemnity Arrangements Pre-Regs & Students FAQs Coronavirus (COVID-19)